NCT04569383View on ClinicalTrials.gov

Safety and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S and a Booster Vaccination With a Licensed Vaccine Against COVID-19

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 5, 2020

Primary Completion Date

August 24, 2021

Study Completion Date

August 24, 2021

Conditions
Covid19
Interventions
BIOLOGICAL

MVA-SARS-2-S vaccinations (days 0 & 28)

Vaccination with MVA-SARS-2-S in two escalating dose regimens

BIOLOGICAL

Comirnaty

Vaccination with Comirnaty (21 day interval)

Trial Locations (1)

20251

CTC North GmbH & Co KG at the University Medical Center Hamburg-Eppendorf, Hamburg

Sponsors
All Listed Sponsors
collaborator

German Center for Infection Research

OTHER

collaborator

Philipps University Marburg

OTHER

collaborator

Ludwig-Maximilians - University of Munich

OTHER

lead

Universitätsklinikum Hamburg-Eppendorf

OTHER

NCT04569383 - Safety and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S and a Booster Vaccination With a Licensed Vaccine Against COVID-19 | Biotech Hunter | Biotech Hunter